Shanghai Fosun Pharmaceutical Group Co Ltd (2196)

Hong Kong


Symbol		Exchange		Currency
2196	·	Hong Kong	·	HKD	Delayed
600196	·	Shanghai	·	CNY	Delayed

Currency in HKD

2196 Pro Research

17.64

+0.25(+1.44%)

Closed·03:59:59

Fair Value

Unlock Value

Day's Range

17.51

17.83

52 wk Range

14.90

26.82

2196 Income Statement

Assess the Shanghai Fosun Pharmaceutical income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the 2196 net worth.

Period Ending:

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

aa.aa

39,011.18

43,951.55

41,399.54

41,067.2

41,661.61

Total Revenues Growth

aa.aa

+28.72%

+12.66%

-5.81%

-0.8%

+1.45%

Cost Of Revenues

aa.aa

20,294.4

23,256.02

21,716.65

21,425.93

20,878.04

Gross Profit

aa.aa

18,716.79

20,695.53

19,682.89

19,641.27

20,783.57

Gross Profit Growth

aa.aa

+13.37%

+10.57%

-4.89%

-0.21%

+5.82%

Gross Profit Margin %

aa.aa

47.98%

47.09%

47.54%

47.83%

49.89%

Other Operating Expenses, Total

aa.aa

16,179.98

17,275.4

18,498.56

16,667.53

17,993.43

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+16.48%	+6.77%	+7.08%	-9.9%	+7.95%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	3,837.3	4,302.09	4,346.04	3,644.36	4,012.56
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	12,400.54	13,061.46	14,197.51	13,070.7	13,899.76
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-57.86	-88.15	-44.99	-47.52	81.12

Operating Income

aa.aa

2,536.81

3,420.13

1,184.33

2,973.74

2,790.15

Operating Income Growth

aa.aa

-3.1%

+34.82%

-65.37%

+151.09%

-6.17%

EBIT Margin %

aa.aa

6.5%

7.78%

2.86%

7.24%

6.7%

Net Interest Expenses

aa.aa

4,035.07

3,696.67

2,540.81

1,045.9

2,798.93

Net Interest Expenses Growth

aa.aa

+151.78%

-8.39%

-31.27%

-58.84%

+167.61%

Interest Expense, Total

aa.aa

-822.54

-963.81

-1,324.83

-1,431.91

-1,265.35

Interest And Investment Income

aa.aa

4,857.61

4,660.48

3,865.64

2,477.82

4,064.28

Other Non Operating Expenses, Total

aa.aa

123.57

30.58

-44.7

-54.77

-190.62

EBT, Excl. Unusual Items

aa.aa

6,695.45

7,147.38

3,680.43

3,964.87

5,398.46

Gain (Loss) On Sale Of Assets

aa.aa

-15.42

125.6

5.56

371.01

69.35

Other Unusual Items, Total

aa.aa

-377.17

-20.24

67.23

-50.66

6.78

EBT, Incl. Unusual Items

aa.aa

6,042.67

4,574.38

3,264.57

4,169.28

5,111.98

EBT, Incl. Unusual Items Growth

aa.aa

+29.18%

-24.3%

-28.63%

+27.71%

+22.61%

EBT, Incl. Unusual Items Margin

aa.aa

15.49%

10.41%

7.89%

10.15%

12.27%

Income Tax Expense

aa.aa

1,066.4

626.92

369.5

656.84

864.05

Net Income to Company

aa.aa

4,976.27

3,947.46

2,895.06

3,512.44

4,247.93

Minority Interest

aa.aa

-247.56

-216.66

-508.8

-742.55

-877.37

Net Income

aa.aa

4,728.71

3,730.8

2,386.27

2,769.89

3,370.56

Net Income Growth

aa.aa

+29.1%

-21.1%

-36.04%

+16.08%

+21.69%

Net Income Margin %

aa.aa

12.12%

8.49%

5.76%

6.74%

8.09%

Preferred Dividend and Other Adjustments

aa.aa

1.05

Net Income to Common Excl. Extra Items

aa.aa

4,728.71

3,730.8

2,385.22

2,769.89

3,370.56

Basic EPS - Continuing Operations

aa.aa

1.85

1.43

0.89

1.04

1.27

Basic EPS - Continuing Operations Growth

aa.aa

+29.1%

-22.45%

-37.56%

+16.09%

+22.79%

Diluted EPS - Continuing Operations

aa.aa

1.85

1.43

0.89

1.04

1.27

Diluted EPS - Continuing Operations Growth

aa.aa

+29.1%

-22.5%

-37.52%

+16.09%

+22.44%

Basic Weighted Average Shares Outstanding

aa.aa

2,562.9

2,607.38

2,669.66

2,670.41

2,646.29

Diluted Weighted Average Shares Outstanding

aa.aa

2,562.9

2,607.38

2,669.91

2,670.41

2,646.29

Dividend Per Share

aa.aa

0.56

0.42

0.27

0.32

0.39

Dividend Per Share Growth

aa.aa

+30.23%

-25%

-35.71%

+18.52%

+21.88%

EBITDA

aa.aa

4,183.68

5,540.96

3,883.12

5,555.56

5,883.39

EBITDA Growth

aa.aa

+2.46%

+32.44%

-29.92%

+43.07%

+5.9%

EBITDA Margin %

aa.aa

10.72%

12.61%

9.38%

13.53%

14.12%

EBIT

aa.aa

2,536.81

3,420.13

1,184.33

2,973.74

2,790.15

* In Millions of CNY (except for per share items)

FAQ

What was Shanghai Fosun Pharmaceutical’s revenue at year end?

At the end of the last reported fiscal year, Shanghai Fosun Pharmaceutical (2196) recorded total revenue of 41,661.61 million CNY.

How much revenue did Shanghai Fosun Pharmaceutical report in the most recent quarter?

In its most recent quarterly earnings report, Shanghai Fosun Pharmaceutical posted revenue of 10,368.75 million CNY.

What was Shanghai Fosun Pharmaceutical’s net income for the year?

For the full year, Shanghai Fosun Pharmaceutical reported net income of 3,370.56 million CNY.

How much net income did Shanghai Fosun Pharmaceutical post in the last quarter?

In the most recent quarter, Shanghai Fosun Pharmaceutical (2196) posted net income of 850.64 million CNY.

What was Shanghai Fosun Pharmaceutical’s gross profit for the year?

Gross profit for the year was reported at 20,783.57 million CNY.

How much gross profit did Shanghai Fosun Pharmaceutical generate last quarter?

Shanghai Fosun Pharmaceutical recorded gross profit of 5,139.31 million CNY in its latest quarterly report.

What was Shanghai Fosun Pharmaceutical’s annual operating income?

For the full year, Shanghai Fosun Pharmaceutical (2196) reported operating income of 2,790.15 million CNY.

What was Shanghai Fosun Pharmaceutical’s operating income last quarter?

Quarterly operating income was 505.27 million CNY.

What was Shanghai Fosun Pharmaceutical’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at 1,244.54 million CNY.

What was the quarter-over-quarter change in EBITDA for Shanghai Fosun Pharmaceutical?

EBITDA changed by -21.58% million CNY compared to the last quarter.

What is Shanghai Fosun Pharmaceutical’s most recent gross profit margin?

The latest reported gross profit margin for Shanghai Fosun Pharmaceutical (2196) is 49.57% million CNY.

What is Shanghai Fosun Pharmaceutical’s most recent net income margin?

Net income margin based on recent financials is 8.20% million CNY.

What is Shanghai Fosun Pharmaceutical’s most recent EBIT margin?

Shanghai Fosun Pharmaceutical reported an EBIT margin of 4.87% million CNY based on current figures.

How did Shanghai Fosun Pharmaceutical’s revenue change compared to the previous quarter?

Revenue changed by 2.93% million CNY compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Shanghai Fosun Pharmaceutical?

In the latest quarter, gross profit changed by 2.65% million CNY from the previous quarter.

S&P/TSX

35,517.61

-283.28

-0.79%

S&P/TSX 60

2,088.64

-13.80

-0.66%

US 30

51,595.30

-233.3

-0.45%

US 500

7,703.20

-40.3

-0.52%

S&P 500 VIX

15.95

+1.08

+7.26%

DAX

25,530.46

+134.24

+0.53%

Dollar Index

100.895

+0.187

+0.19%

Market Movers

Name	Last	Chg. %	Vol.
TC Energy	82.90	-0.32%	1.79M
Canadian Imperial Bank	159.12	-0.33%	891.38K
Shopify Inc	195.53	-2.82%	338.45K
RBC	286.06	+0.15%	159.21K
Agnico Eagle Mines	262.98	-4.41%	163.24K
Celestica Inc.	500.37	-3.16%	89.14K
Canadian Natural	68.02	+1.27%	586.87K

Name	Last	Chg. %	Vol.
Enerev5 Metals	0.0100	+100.00%	86.25K
Martello Tech	0.0100	+100.00%	26.28K
Slate Grocery REIT	17.51	+62.88%	1.91M
Galore Resources	0.0150	+50.00%	1.00K
TempraMed Tech	0.56	+33.33%	4.50K
IC Holdings	0.57	+26.67%	21.00K
ILC Critical Minerals	0.025	+25.00%	5.08K

Name	Last	Chg. %	Vol.
Mcf Energy	0.02	-25.00%	2.59M
Seasif Exploration	0.0050	-50.00%	500.00K
Big Tree Carbon	0.0100	-33.33%	4.65K
Fjordland Exploration	0.1000	-33.33%	7.12K
Sonoro Energy	0.0150	-25.00%	42.29K
Sleeping Giant Capital	0.06	-25.00%	1.71K
Cascadero Copper	0.0150	-25.00%	2.00K

Trending Stocks

Name	Last	Chg. %	Vol.
Air Canada	26.60	-2.71%	304.10K
Equinox Gold	16.17	-4.15%	1.13M
BCE Inc	29.30	-1.31%	624.45K
Toronto Dominion Bank	170.65	-0.02%	169.91K
HIVE Digital Tech	4.3400	-2.69%	346.56K

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaaa Aaaaa	16.45	+74.69%	28.75
Aaaaaaaaaaa	16.56	+59.35%	26.31
Aaa Aa	95.24	+57.56%	149.10
Aaaa Aa	1.470	+53.53%	2.241
Aa A Aaaaaaa	30.92	+53.14%	47.14
Aaaaaaaaaaaa	15.56	+52.98%	23.80
A Aa A Aaaa	2.3200	+51.81%	3.4917

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaaa Aaaaa	16.45	+74.69%	28.75
Aaaaaaaaaaa	16.56	+59.35%	26.31
Aaa Aa	95.24	+57.56%	149.10
Aaaa Aa	1.470	+53.53%	2.241
Aa A Aaaaaaa	30.92	+53.14%	47.14
Aaaaaaaaaaaa	15.56	+52.98%	23.80
A Aa A Aaaa	2.3200	+51.81%	3.4917

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Shanghai Fosun Pharmaceutical Group Co Ltd (2196)

2196 Income Statement

FAQ

What was Shanghai Fosun Pharmaceutical’s revenue at year end?

How much revenue did Shanghai Fosun Pharmaceutical report in the most recent quarter?

What was Shanghai Fosun Pharmaceutical’s net income for the year?

How much net income did Shanghai Fosun Pharmaceutical post in the last quarter?

What was Shanghai Fosun Pharmaceutical’s gross profit for the year?

How much gross profit did Shanghai Fosun Pharmaceutical generate last quarter?

What was Shanghai Fosun Pharmaceutical’s annual operating income?

What was Shanghai Fosun Pharmaceutical’s operating income last quarter?

What was Shanghai Fosun Pharmaceutical’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Shanghai Fosun Pharmaceutical?

What is Shanghai Fosun Pharmaceutical’s most recent gross profit margin?

What is Shanghai Fosun Pharmaceutical’s most recent net income margin?

What is Shanghai Fosun Pharmaceutical’s most recent EBIT margin?

How did Shanghai Fosun Pharmaceutical’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for Shanghai Fosun Pharmaceutical?

Trending Stocks